BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Li D, Gruber SB, Iyer S, Gupta S, Tejani M. Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States. World J Gastrointest Oncol 2023; 15(10): 1796-1806 [PMID: 37969411 DOI: 10.4251/wjgo.v15.i10.1796]
URL: https://www.wjgnet.com/1948-5204/full/v15/i10/1796.htm
Number Citing Articles
1
Xiaomo Xiong, Jeff Jianfei Guo. Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USAPharmacoEconomics 2024;  doi: 10.1007/s40273-024-01453-0